Movement & fitness

Polymyalgia rheumatica: shoulder and hip stiffness, diagnostic mimics, steroid exposure, relapse, and newer evidence

7 sources · Latest source check 2026-10-09 UTC

On this page

Polymyalgia rheumatica, or PMR, is an inflammatory condition causing pain and stiffness, particularly around the shoulders, neck and hips. Morning stiffness is characteristic, and the condition occurs mainly after age fifty. It can make dressing, raising the arms or getting out of a chair difficult.[1][4]

The important distinctions begin with the clinical problem

The important distinctions begin with the clinical problem
Question	Why it matters
Typical PMR pattern	Shoulder/hip-region pain and prolonged morning stiffness.[1]
Inflammation markers	Raised CRP or ESR supports context but does not identify the cause alone.[2]
Bursae and nearby structures	Inflamed shoulder or hip bursae may contribute to the pain pattern.[4]
Associated giant-cell arteritis	Artery inflammation creates a different and potentially urgent problem.[1]

Muscle aching does not identify a muscle-fiber disorder

The ACR discusses inflammation of bursae around shoulders or hips as a possible contributor to PMR symptoms. Pain near a muscle therefore does not establish which tissue is inflamed or prove a muscle tear. The condition’s everyday description and its anatomical explanation operate at different levels.[4]

Assessment considers alternatives before accepting a familiar pattern

The NHS describes overlap with rheumatoid arthritis and evaluation of other possible explanations, including thyroid problems or infection. History, examination, selected blood tests and sometimes imaging contribute. A person’s age and shoulder symptoms are clues, rather than permission to skip assessment of a new or unusual presentation.[2]

Inflammatory markers are neither a unique label nor a complete exclusion test

The NHS notes that high CRP or ESR can occur in many conditions, while normal results make a typical PMR diagnosis less likely.[2]

The ACR notes that some people with PMR lack elevated markers. A less typical result changes the assessment, but an isolated test does not decide every case.[4]

Rapid symptom relief and long-term cure are different outcomes

The NHS describes prednisolone as the main treatment, with improvement sometimes occurring within days. That response does not establish a cure. Treatment is reduced gradually under supervision, with follow-up of symptoms and adverse effects. The page warns against suddenly stopping steroids because doing so can make a person very unwell.[3]

The treatment’s benefits need to be weighed alongside its burden

The NHS discusses steroid-related bone weakening, blood-pressure changes, infection risk and effects on mood, among other problems. Follow-up therefore examines more than whether aching has eased. A favorable response to anti-inflammatory treatment does not make ongoing exposure harmless, and new symptoms may reflect the disease, treatment or another condition.[3]

Recovery and relapse do not follow one universal calendar

The NHS explains that treatment can last a long time and that symptoms may return during or after reduction. A typical duration in a patient-information page is not a promise of remission by that date. A recurrence needs reassessment and an agreed care plan rather than an automatic self-directed return to an earlier prescription.[3]

The December 2025 regional update adds newer treatment context

German, Austrian and Swiss society recommendations were published online in December 2025, with a February 2026 issue. Their literature search covered July 2016 through January 2024. They emphasize confirmation of diagnosis, individualized treatment, monitoring and limiting glucocorticoid exposure. Selected IL-6-receptor blockade is considered for relapse and some high-risk new presentations.[5]

The document concerns isolated PMR without clinical signs of giant-cell arteritis and excludes checkpoint-inhibitor-related PMR-like syndromes. Its recommendations combine evidence and expert judgment. These scope limits matter: it cannot simply be used as the treatment pathway for someone with suspected artery inflammation. Complete recommendation tables were not independently appraised here.[5]

A further EULAR update appeared in July 2026

The recommendations titled “2025 EULAR” were actually published online on 21 July 2026 and jointly cover PMR and primary large-vessel vasculitis. The abstract distinguishes specialist assessment and confirmation for PMR from urgent action for suspected giant-cell arteritis. It also considers selected steroid-sparing therapy. The full recommendations and supporting reviews remain unappraised here.[6]

SAPHYR studied relapse during glucocorticoid reduction

Spiera and colleagues’ 2023 trial randomized 118 people with relapsing PMR to sarilumab with a shorter prednisone taper or placebo with a longer taper. At fifty-two weeks, sustained remission occurred in 28% versus 10%: an 18-percentage-point difference, 95% confidence interval 4–32. The outcome combined symptoms, CRP, absence of flare and adherence to the planned taper.[7]

Cumulative steroid exposure was lower, but the comparison included different taper schedules rather than isolating drug effects under identical schedules. Neutropenia, arthralgia, diarrhea and treatment-related discontinuation were more frequent with sarilumab. Sanofi and Regeneron funded the trial. Its findings do not establish a universal prescription or resolve long-term harms.[7]

New headache, jaw pain or visual symptoms change the priority

PMR can occur with giant-cell arteritis. The NHS identifies new headache, scalp tenderness, jaw pain during chewing and visual disturbance as reasons for urgent medical assessment because vision can be threatened. These should not be folded into an ordinary PMR flare or delayed while trying a lifestyle measure.[1]

Treatment aims include ordinary daily abilities

The ACR describes the impact on dressing, rising from furniture, sleep and arm movement. Restoring these abilities matters alongside blood-test trends. Improvements in one measure can occur without settling every practical difficulty; support and follow-up should reflect the person’s changing daily needs.[4]

Evidence & uncertainty

There is no single confirming test. Similar symptoms can arise from other diseases, and treatment response alone is not a complete diagnosis. Glucocorticoids can relieve symptoms but have important harms. Newer guidance considers steroid-sparing treatment in selected situations; a relapse trial should not be generalized to every newly diagnosed person.[2][5][7]

Selected-source overview · Independent review pending

Published questions

Which age context is typical for polymyalgia rheumatica?

Selected-source overview · Independent review pending. Read the evidence context.

It occurs mainly after age fifty.[4]

Evidence behind this answer

Polymyalgia Rheumatica
professional association explanation · 2025
Selected relevant original official page passages inspected · February 2025: age, bursae, marker-negative context and everyday function